The Journal of Immunology, Vol 146, Issue 6 1806-1811, Copyright © 1991 by American Association of Immunologists

ARTICLES

Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies

FS Jin, RJ Youle, VG Johnson, J Shiloach, R Fass, DL Longo and SH Bridges
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.

Treatment of normal mice with a mAb to CD4 (GK1.5) was explored as a means of inhibiting the antibody response to an immunotoxin. Three days of pretreatment with 200 micrograms of GK1.5 completely abrogated the primary antibody response to a 3-micrograms dose of a mutant diphtheria toxin conjugated to an anti-transferrin receptor antibody. The same dose and schedule of anti-CD4 antibody significantly reduced and delayed, but did not prevent, the anamnestic antitoxin response in animals that had been previously primed to the immunotoxin. Three daily injections of anti-CD4 antibodies followed by weekly doses of immunotoxin resulted in a 3-wk delay in the development of antitoxin antibodies, and the kinetics of the antitoxin response correlated with the kinetics of recovery of CD4+ T cells in the spleen and lymph nodes. The antitoxin response to repeated doses of immunotoxin was completely abrogated when anti-CD4 antibodies were given every 2 wk throughout the course of immunotoxin treatment. Thus, transient depletion of Th cells during treatment can block the immune response to an immunotoxin. There was no evidence of tolerance induction with this regimen.

This article has been cited by other articles:

				S. Kar, C. Metz, and D. McMahon-Pratt CD4+ T Cells Play a Dominant Role in Protection against New World Leishmaniasis Induced by Vaccination with the P-4 Amastigote Antigen Infect. Immun., June 1, 2005; 73(6): 3823 - 3827. [Abstract] [Full Text] [PDF]

				D. Castelletti and M. Colombatti Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response Int. Immunol., April 1, 2005; 17(4): 365 - 372. [Abstract] [Full Text] [PDF]

				A. E. Frankel Reducing the Immune Response to Immunotoxin: Commentary re R. Hassan et al., Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. Clin. Cancer Res., 10: 16-18, 2004. Clin. Cancer Res., January 1, 2004; 10(1): 13 - 15. [Full Text] [PDF]

				D. J. Herzyk, E. R. Gore, R. Polsky, K. L. Nadwodny, C. C. Maier, S. Liu, T. K. Hart, A. G. Harmsen, and P. J. Bugelski Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice Infect. Immun., February 1, 2001; 69(2): 1032 - 1043. [Abstract] [Full Text] [PDF]

				P J Bugelskil, D J Herzykl, S Rehm, A G Harmsen, E V Gore, D M Williams, B E Maleeff, A M Badger, A Truneh, S R O'Brien, et al. Preclinical development of keliximab, a PrimatizedTM anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies Human and Experimental Toxicology, April 1, 2000; 19(4): 230 - 243. [Abstract] [PDF]